All In Biotech

Drug Trial Radar · NCT07535931

Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis

A Phase I/Ⅱ Clinical Trial for HS_SW01 Cells Injection in the Treatment of Systemic Sclerosis

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Apr 10, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
Collaborators
Southern Medical University, China
First posted
Apr 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection(HS\_SW01 Cells injection) in patients with systemic sclerosis, and to further explore its pharmacokinetics(PK), immunological profile and preliminary efficacy. Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.

Conditions

  • Systemic Sclerosis (SSc)

Interventions

  • HS_SW01 cells injectionDrug

    A single dose of 0.5×10⁶ cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.

  • HS_SW01 cells injectionDrug

    A single dose of 1×10⁶ cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.

  • HS_SW01 cells injectionDrug

    A single dose of 2×10⁶ cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of DLTTime frame: Within 28 Days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.